Amide compound
AssigneeTakeda Pharmaceutical Company Limited
InventorsSatoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
Life of this patent
Estimating the term…
Abstract
The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.
Claims12
-16. (canceled)
A method for the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis or systemic lupus erythematosus (SLE), which comprises administering an effective amount of a compound represented by the following formula (I):
- wherein
- Ring A is a benzene ring optionally further substituted by 1 to 3 substituents selected from
- (1) a halogen atom, and
- (2) a cyano group;
- R1 is
- (1) a group represented by the formula:
- -Q(R1a)(R1b)(R1c)
- wherein
- Q is a carbon atom or a silicon atom, and
- R1a, R1b and R1c are each independently a C1-6 alkyl group, or
- (2) a neopentyl group;
- R2 is
- (1) a group represented by the formula:
- wherein
- R5 is
- (A) a C1-6 alkyl group optionally substituted by 1 to 3 C1-6 alkoxy groups, or
- (B) a C1-6 alkoxy group,
- (2) a bicyclic fused heterocyclic group selected from dihydrobenzofuryl and indazolyl, each optionally substituted by 1 to 3 C1-6 alkyl groups, or
- (3) a group represented by the formula -L-Z1:
- wherein
- L is a bond;
- and
- Z1 is
- (A) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, or
- (B) tetrahydropyranyl;
- R3 is
- (1) a hydrogen atom, or
- (2) a C1-6 alkyl group;
- and
- R4 is
- (1) a C1-6 alkyl group optionally substituted by 1 to 7 substituents selected from
- (a) a 3- to 8-membered monocyclic non-aromatic heterocyclic group selected from dihydropyrimidinyl, dihydropyridyl, dihydropyridazinyl, imidazolidinyl, tetrahydropyranyl, morpholinyl, piperidyl and tetrahydropyrimidinyl, each optionally substituted by 1 to 3 substituents selected from
- (i) an oxo group, and
- (ii) a C1-6 alkyl group,
- (b) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
- (i) a C1-6 alkyl group, and
- (ii) a hydroxy group,
- (c) a 8- to 14-membered fused bicyclic aromatic heterocyclic group selected from indazolyl and benzimidazolyl,
- (d) a halogen atom,
- (e) a hydroxy group,
- (f) a cyano group,
- (g) a carboxy group,
- (h) a C1-6 alkylsulfonyl group, and
- (i) an amino group optionally mono- or di-substituted by C1-6 alkyl-carbonyl group(s),
- (2) a 3- to 8-membered monocyclic non-aromatic heterocyclic group selected from pyrrolidinyl, oxazolidinyl, azetidinyl, piperidyl and tetrahydropyranyl, each optionally substituted by 1 to 3 substituents selected from
- (a) an oxo group,
- (b) a hydroxy group,
- (c) a halogen atom, and
- (d) a C1-6 alkyl-carbonyl group,
- (3) a 5-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 hydroxy groups,
- (4) a C3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, or
- (5) an amino group optionally mono- or di-substituted by C1-6 alkyl group(s), provided that
- α-(acetylamino)-N-[4-(1,1-dimethylethyl)phenyl]-cyclopentaneacetamide
- is excluded,
- or a salt thereof, to a mammal.
Dependencies are inferred from the claim text.